{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:56Z","timestamp":1792699976915,"version":"4.5.0"},"reference-count":29,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2016,11,19]],"date-time":"2016-11-19T00:00:00Z","timestamp":1479513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during six regional French conferences (Bordeaux, Lyon, Marseille, Nice, Paris, and Strasbourg). Data on the characteristics of practice, prescription rates of antipsychotic, and information sources about their clinical decisions were collected. Most psychiatrists used second-generation antipsychotics (SGAs), and preferentially an oral formulation, in the treatment of schizophrenia. LAI SGAs were prescribed to 30.4% of schizophrenic patients. The duration and type of practice did not influence the class or formulation of antipsychotics used. The clinicians following the higher percentage of schizophrenic patients were associated with a higher use of LAI antipsychotics and a lower use of oral SGAs. Personal experience, government regulatory approval, and guidelines for the treatment of schizophrenia were the three main contributing factors guiding clinicians\u2019 decision-making regarding the treatment of schizophrenia. The more clinicians follow schizophrenic patients, the more they use LAI antipsychotics. The development of specialized programs with top specialists should lead to better use of LAI antipsychotics in the treatment of schizophrenia.<\/jats:p>","DOI":"10.3390\/ijms17111935","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T11:16:05Z","timestamp":1479726965000},"page":"1935","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics"],"prefix":"10.3390","volume":"17","author":[{"given":"Ludovic","family":"Samalin","sequence":"first","affiliation":[{"name":"Centre Hospitalier et Universitaire, Department of Psychiatry, University of Auvergne, EA 7280, 63000 Clermont-Ferrand, France"},{"name":"French Society for Biological Psychiatry and Neuropsychopharmacology, CH Sainte Anne, 75674 Paris, France"},{"name":"Fondation FondaMental, H\u00f4pital Albert Chenevier, Depatment of Psychiatry, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Garnier","sequence":"additional","affiliation":[{"name":"Centre Hospitalier et Universitaire, Department of Psychiatry, University of Auvergne, EA 7280, 63000 Clermont-Ferrand, France"},{"name":"Fondation FondaMental, H\u00f4pital Albert Chenevier, Depatment of Psychiatry, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candy","family":"Auclair","sequence":"additional","affiliation":[{"name":"Centre Hospitalier et Universitaire, Department of Public Health, University of Auvergne, EA 4681 PEPRADE, 63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7438-8990","authenticated-orcid":false,"given":"Pierre-Michel","family":"Llorca","sequence":"additional","affiliation":[{"name":"Centre Hospitalier et Universitaire, Department of Psychiatry, University of Auvergne, EA 7280, 63000 Clermont-Ferrand, France"},{"name":"French Society for Biological Psychiatry and Neuropsychopharmacology, CH Sainte Anne, 75674 Paris, France"},{"name":"Fondation FondaMental, H\u00f4pital Albert Chenevier, Depatment of Psychiatry, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0924-9338(14)70001-X","article-title":"Treatment of early episode in patients with schizophrenia: The role of long acting antipsychotics","volume":"29","author":"Heres","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Geerts, P., Martinez, G., and Schreiner, A. (2013). Attitudes towards the administration of long-acting antipsychotics: A survey of physicians and nurses. BMC Psychiatry, 13.","DOI":"10.1186\/1471-244X-13-58"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4088\/JCP.12r08167","article-title":"Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: Synthesizing results across different research designs","volume":"74","author":"Kirson","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2045125314540297","article-title":"The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal","volume":"4","author":"Brissos","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","article-title":"Efficacy and safety of second-generation long-acting injections in schizophrenia: A meta-analysis of randomized-controlled trials","volume":"28","author":"Kempton","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1177\/088740341305805s02","article-title":"Long-acting injectable antipsychotics: Evidence of effectiveness and use","volume":"58","author":"Manchanda","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.schres.2014.04.024","article-title":"How study designs influence comparative effectiveness outcomes: The case of oral versus long-acting injectable antipsychotic treatments for schizophrenia","volume":"156","author":"Alphs","year":"2014","journal-title":"Schizophr. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1192\/bjp.195.52.s63","article-title":"Clinical guideline recommendations for antipsychotic long-acting injections","volume":"52","author":"Kane","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/070674371105600608","article-title":"Long-acting injectable antipsychotics: An expert opinion from the Association des m\u00e9decins psychiatres du Qu\u00e9bec","volume":"56","author":"Stip","year":"2011","journal-title":"Can. J. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1177\/088740341305805s05","article-title":"Long-acting injectable antipsychotics: Recommendations for clinicians","volume":"58","author":"Malla","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Llorca, P.M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., and Samalin, L. (2013). Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry, 13.","DOI":"10.1186\/1471-244X-13-340"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0269881109104882","article-title":"Psychiatrists\u2019 use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: Comparisons over 5 years","volume":"24","author":"Patel","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/NMD.0b013e31829829c4","article-title":"Clinicians\u2019 attitudes toward the use of long-acting injectable antipsychotics","volume":"201","author":"Samalin","year":"2013","journal-title":"J. Nerv. Mental Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1017\/S109285291300014X","article-title":"\u201cMeta-guidelines\u201d for the management of patients with schizophrenia","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Verdoux, H., Pambrun, E., Tournier, M., Bezin, J., and Pariente, A. (2016). Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. Schizophr. Res., in press.","DOI":"10.1016\/j.schres.2016.09.014"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.encep.2010.04.001","article-title":"Evaluation of prescription practices of long acting injectable risperidone in French hospitals","volume":"37","author":"Bret","year":"2011","journal-title":"Encephale"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1192\/bjp.195.52.s37","article-title":"Antipsychotic long-acting injections: Prescribing practice in the UK","volume":"52","author":"Barnes","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5414\/CPP46245","article-title":"Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China","volume":"46","author":"Xiang","year":"2008","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0033291702006797","article-title":"Psychiatrists\u2019 attitudes to maintenance medication for patients with schizophrenia","volume":"33","author":"Patel","year":"2003","journal-title":"Psychol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/YIC.0b013e32835d30ae","article-title":"Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients","volume":"28","author":"Kim","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1177\/088740341305805s04","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part II\u2014Physician perspectives","volume":"58","author":"Iyer","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.4088\/JCP.v67n1216","article-title":"Attitudes of psychiatrists toward antipsychotic depot medication","volume":"67","author":"Heres","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/NMD.0b013e3182125d4c","article-title":"Adherence to guidelines by French psychiatrists in their real world of clinical practice","volume":"199","author":"Samalin","year":"2011","journal-title":"J. Nerv. Mental Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0013-7006(13)70121-0","article-title":"French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics","volume":"39","author":"Samalin","year":"2013","journal-title":"Encephale"},{"key":"ref_26","first-page":"CD010669","article-title":"Tools developed and disseminated by guideline producers to promote the uptake of their guidelines","volume":"22","author":"Flodgren","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10597-011-9389-6","article-title":"Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center","volume":"47","author":"Velligan","year":"2011","journal-title":"Community Mental Health J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.eurpsy.2015.05.004","article-title":"A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap","volume":"30","author":"Fond","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"ref_29","unstructured":"Conseil National de l\u2019Ordre des M\u00e9decins Atlas de la D\u00e9mographie M\u00e9dicale en France: Situation Au 1er Janvier 2014. Available online: https:\/\/www.conseil-national.medecin.fr\/sites\/default\/files\/atlas_2014.pdf."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/11\/1935\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:27:03Z","timestamp":1760210823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/11\/1935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,19]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11]]}},"alternative-id":["ijms17111935"],"URL":"https:\/\/doi.org\/10.3390\/ijms17111935","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201611.0056.v1","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,19]]}}}